Trial · NCT07904364
Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
NCT07904364, Not yet recruiting, Mardin Artuklu University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain. Trials, record NCT07904364. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904364
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
- NCT number
- NCT07904364
- Status
- Not yet recruiting
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Mardin Artuklu University
- Conditions
- Myofascial Pain Syndrome - Neck
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Agreement Between CSI and IASP Nociplastic Pain Classifications | baseline | Agreement between the Central Sensitization Inventory (CSI) and the International Association for the Study of Pain (IASP) clinical nociplastic pain classification will be quantified using Cohen's kappa coefficient with a 95% confidence interval. CSI scores will be categorized as below 40 or 40 and above. IASP classifications will be dichotomized as not meeting the criteria or meeting the criteria for at least possible nociplastic pain (possible or probable). Cohen's kappa ranges from -1 to 1, with 1 indicating perfect agreement, 0 indicating agreement expected by chance, and negative values indicating less agreement than expected by chance. |
| Secondary | Overall Discordance Rate Between CSI and IASP Classifications | baseline | The percentage of participants with discordant CSI and IASP classifications will be calculated. Discordance is defined as either a CSI score of 40 or higher without meeting the IASP criteria for nociplastic pain, or a CSI score below 40 while meeting the IASP criteria for at least possible nociplastic pain. The overall discordance rate will be reported as a percentage with a 95% confidence interval calculated using the Wilson method. |
| Secondary | Discordance Rate for CSI-Positive and IASP-Negative Classification | baseline | The percentage of all evaluated participants with a CSI score of 40 or higher who do not meet the IASP clinical criteria for nociplastic pain will be calculated. This represents one direction of disagreement between the two classification approaches. The proportion will be reported with a 95% confidence interval using the Wilson method. |
| Secondary | Discordance Rate for CSI-Negative and IASP-Positive Classification | baseline | The percentage of all evaluated participants with a CSI score below 40 who meet the IASP criteria for at least possible nociplastic pain will be calculated. The IASP-positive category includes possible and probable nociplastic pain. This represents the opposite direction of disagreement between the two classification approaches. The proportion will be reported with a 95% confidence interval using the Wilson method. |
| Secondary | Differences in IPQ-R Emotional Representations Scores Across CSI-IASP Classification Groups | baseline | Emotional responses to illness will be assessed using the Emotional Representations subscale of the Revised Illness Perception Questionnaire (IPQ-R). This subscale consists of 6 items scored from 1 to 5, yielding a total score ranging from 6 to 30. Higher scores indicate stronger negative emotional responses to illness, whereas lower scores indicate fewer negative emotional responses. Scores will be compared across four groups defined by CSI classification (below 40 versus 40 or higher) and IASP classification (not meeting criteria versus at least possible nociplastic pain). Multivariable linear regression will be used to assess group differences after adjustment for pain severity (NRS) and neck-related disability (NDI). Adjusted mean differences and 95% confidence intervals will be reported. |
| Secondary | Agreement Between CSI Classification and Probable IASP Nociplastic Pain | baseline | An additional agreement analysis will be conducted using only the probable nociplastic pain category as the positive IASP classification. Participants not meeting the IASP criteria and those classified as having possible nociplastic pain will form the comparison category. CSI scores will be classified as below 40 or 40 and above. Agreement will be quantified using Cohen's kappa coefficient with a 95% confidence interval. |
| Other | IPQ-R Consequences Score Across CSI-IASP Classification Groups | baseline | Perceived consequences of illness will be assessed using the Consequences subscale of the Revised Illness Perception Questionnaire (IPQ-R). This subscale consists of 6 items scored from 1 to 5, yielding a total score ranging from 6 to 30. Higher scores indicate greater perceived negative consequences of illness, while lower scores indicate fewer perceived negative consequences. Scores will be compared across the four groups defined by CSI (below 40 versus 40 or higher) and IASP (not meeting criteria versus at least possible nociplastic pain) classifications as an exploratory analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904364
GET https://conductscience.org/api/trials/v1/NCT07904364/registered